United Kingdom (UK)
Recombinant monoclonal antibody to EPHA3. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from synthetic construct FA225-C10.
UniProt Accession Number of Target Protein: P29320
Alternative Name(s) of Target: Ephrin type-A receptor 3; EPH-like kinase 4; EK4; hEK4; Human embryo kinase; HEK; Tyrosine-protein kinase TYRO4; Tyrosine-protein kinase receptor ETK1; Eph-like tyrosine kinase 1
Immunogen: The original mouse parental antibody IIIA4 was generated by intraperitoneal immunization of BALB/c mice with LK63 cells. This antibody was synthetically engineered to mimic a binding specificity of the original IIIA4, by grafting the CDRs of the parental antibody onto human framework segments.
Specificity: This antibody is specific for EPHA3.
Application Notes: This antibody is a humanized affinity improved version of the original mouse parental antibody IIIA4. The binding affinity of this antibody for EphA3 antigen was determined by ELISA. Flow cytometry was performed with this antibody on cells from patients with multiple myeloma (US20110243934). In the xenograft model of leukemia the antibody directly affects the tumor cells with no effect on stromal and vascular elements. In human tumor xenografts of prostate cell line DU-145 in nude mice, FA225-C10 antibody produced a significant inhibition of tumor growth. In this model the tumor cells do not express EphA3 but the tumor stroma and neovasculature express EphA3 and treatment with antibody reduced both tumor stroma and new vessel density (Charmsaz et al., 2014).
Antibody first published in: Varghese et al. Epha3 antibodies for the treatment of multiple myeloma. US20110243934 PMID: